ASMB — Assembly Biosciences, Inc.

Is ASMB overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Assembly Biosciences, Inc. (ASMB) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $33.84. The rating moved from Neutral to Overbought on August 14, 2026.

See all overbought Healthcare stocks →

AI analysis

Assembly Biosciences, Inc. (ASMB) is a development-stage biotech with upside driven by near-term clinical and strategic catalysts set against typical sector risks. The macro and intraday market environment is neutral, placing emphasis on company-specific news. Valuation is supported by a favorable M&A/partnership backdrop for biotech assets, but outcomes remain binary and dependent on data, financing cadence, and competitive dynamics. Expect elevated volatility; positive clinical readouts or strategic deals would be primary upside drivers, while trial setbacks, dilution, or regulatory delays would be key downside scenarios.

Key factors

  • Assembly Biosciences, Inc. (ASMB) has a development-stage pipeline with programmable upside from upcoming clinical data readouts and potential regulatory milestones that are typical catalysts for small-cap biotech re-ratings.
  • Sector M&A and elevated biotech/pharma multiples provide a constructive backdrop for acquisition interest or partnership value realization for companies with differentiated assets.
  • Relative valuation appears attractive versus larger-cap peers given limited commercialization risk to date; this can create asymmetric upside if clinical results are positive or if strategic deals surface.
  • Calm near-term macro and balanced market order flow reduce odds of broad risk-off moves in the immediate window, enabling stock-specific news to drive price action.
  • Limited social sentiment and absence of major new macro or geopolitical headlines in the four-hour window reduces short-term noise, focusing attention on fundamentals and company-specific catalysts.

Risks

  • Binary clinical and regulatory outcomes: negative or inconclusive trial data could materially reduce valuation.
  • Cash runway and financing risk: as a development-stage biotech, future capital raises could be dilutive and pressuring to the share price if required on unfavorable terms.
  • Competitive risk from larger pharmas or adjacent modalities could reduce commercial prospects even if clinical activity shows activity.
  • Execution risk around partnerships, manufacturing scale-up or enrollment delays that can push out expected catalysts.
  • High share-price volatility and low liquidity typical of small-cap biotech names can magnify downside on adverse headlines.

See today's live rating, score and targets

Members see the live hourly rating for ASMB — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.